Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
US11478440B2 · kind B2 · utility
7Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 18, 2018 |
| Grant date | Oct 25, 2022 |
| Priority date | — |
| Expiry date | Apr 18, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a combination product and its use in therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.